- Q3 2025 saw a 2% organic sales growth and a strong increase in Adjusted EBITDA.
- Full-year 2025 Adjusted EBITDA is projected at €2.3 billion, considering €90 million negative FX impact and €50 million lower ANH vitamin contribution.
- The ANH divestment process is expected to conclude in Q4 2025.
- As of October 28, 2025, 85% of the €1 billion share buyback program was completed.
Q3 2025 Performance
dsm-firmenich reported a solid 2% organic sales growth in Q3 2025, despite a challenging prior-year comparison. The company achieved a significant increase in Adjusted EBITDA on a comparable basis, reflecting its strategic focus and operational efficiencies.
2025 Outlook
The full-year 2025 Adjusted EBITDA is now estimated at around €2.3 billion. This forecast accounts for a €90 million negative impact from foreign exchange fluctuations and a €50 million reduction in contributions from vitamins in the Animal Nutrition & Health (ANH) segment.
ANH Divestment
The divestment process for the ANH business is ongoing, with a target to conclude by the fourth quarter of 2025. The company remains committed to exiting this segment as part of its strategic realignment.
Share Buyback Program
As of October 28, 2025, dsm-firmenich had executed approximately 85% of its €1 billion share buyback program, initiated on April 1, 2025, to reduce its issued capital.
